Please use this identifier to cite or link to this item:
Title: Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions
Authors: MARTENS, Pieter 
Lambeets, Seppe
Lau, Chirik Wah
DUPONT, Matthias 
MULLENS, Wilfried 
Issue Date: 2019
Source: ACTA CARDIOLOGICA, 74(2), p. 115-122
Abstract: Background: Sacubitril/valsartan reduced heart failure (HF)-admissions and cardiovascular mortality in the PARADIGM-HF-trial. However, real-world patients are often frailer and less able to tolerate high doses of sacubitril/valsartan. Methods: We performed a retrospective analysis of consecutive patients prescribed sacubitril/valsartan in a single tertiary HF-clinic between December 2016 and January 2018. HF-admissions were assessed in a paired fashion, comparing the amount of antecedent HF-episodes with incident HF-episodes after the initiation. Baseline risk for adverse events was assessed by the EMPHASIS-HF-risk-score. Results: A total of 201-HF-patients were retrospectively identified (age = 68 +/- 11 years, ejection fraction = 29 +/- 8%). Real world patients were older, had higher serum creatinine and a higher New-York Heart-Association (NYHA)-class (p<.05 for all) than in the PARADIGM-HF trial. Over a mean duration of 221 +/- 114 days after initiation of sacubitril/valsartan a total of 23-individual patients experienced at least one HF-episodes. Over the same time period preceding initiation of sacubitril/valsartan, 51 individual patients experienced a HF-episodes (p<.001). Sacubitril/valsartan significantly reduced the rate of incident vs. antecedent HF-admissions, in patients with low or high baseline NYHA-class (II vs. III and IV; p value = 0.019 respectively p =.004) or patients with an EMPHASIS-HF risk score below or above the mean (p =.002 respectively p =.016). Patients older than 75-years exhibited a trend towards HF-reduction. Higher doses of sacubitril/ valsartan were associated with more reduction in incident versus antecedent HF-episodes. Conclusion: Despite being frailer and older, real-world patients exhibit a significant and early reduction in incident HF-hospitalisations following initiation of sacubitril/valsartan. Higher doses might be associated with more reduction in HF-admissions, underscoring the importance of dose uptitration.
Notes: [Martens, Pieter; Lambeets, Seppe; Lau, Chirik Wah; Dupont, Matthias; Mullens, Wilfried] Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium. [Martens, Pieter] Hasselt Univ, Doctoral Sch Med & Life Sci, Diepenbeek, Belgium. [Mullens, Wilfried] Hasselt Univ, Fac Med & Life Sci, Biomed Res Inst, Diepenbeek, Belgium.
Keywords: Sacubitril/valsartan; pharmacology; heart failure; hospitalizations;Sacubitril/valsartan; pharmacology; heart failure; hospitalizations
Document URI:
ISSN: 0001-5385
e-ISSN: 1784-973X
DOI: 10.1080/00015385.2018.1473825
ISI #: 000490261700004
Rights: 2018 Belgian Society of Cardiology
Category: A1
Type: Journal Contribution
Validations: ecoom 2020
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
martens2018 (1).pdf
  Restricted Access
Published version1.16 MBAdobe PDFView/Open    Request a copy
Show full item record


checked on Sep 5, 2020


checked on May 21, 2022

Page view(s)

checked on May 26, 2022


checked on May 26, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.